Jeevan K. Shetty
Royal College of Surgeons in Ireland - Bahrain(BH)
Publications by Year
Research Areas
Hemoglobinopathies and Related Disorders, Blood groups and transfusion, Acute Myeloid Leukemia Research, Myeloproliferative Neoplasms: Diagnosis and Treatment, Erythrocyte Function and Pathophysiology
Most-Cited Works
- → A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia(2020)291 cited
- → The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the Global Burden of Disease Study 2019(2022)234 cited
- → Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial(2023)159 cited
- → Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial(2022)55 cited
- → Copper and ceruloplasmin levels in relation to total thiols and GST in type 2 diabetes mellitus patients(2010)53 cited
- → Pharmacognostical studies on the root ofDecalepis hamiltonii Wt. and Arn., and comparison withHemidesmus indicus (L.) R. Br.(1978)53 cited
- → Relationship between free iron and glycated hemoglobin in uncontrolled type 2 diabetes patients associated with complications(2008)49 cited
- → Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS Study(2022)34 cited
- → Duration of Response to Luspatercept in Patients (Pts) Requiring Red Blood Cell (RBC) Transfusions with Myelofibrosis (MF) - Updated Data from the Phase 2 ACE-536-MF-001 Study(2020)30 cited
- → Luspatercept stimulates erythropoiesis, increases iron utilization, and redistributes body iron in transfusion‐dependent thalassemia(2023)27 cited